Avance Clinical is the largest full-service Australian CRO specializing in delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs.
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient, has been providing CRO services in the region for the past 24 years.
The company’s clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phases 1 and 2 leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.
With experience across more than 105 indications the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.
Avance Clinical delivers customised solutions designed around specific client needs rather than a one size fits all approach.
As a company, Avance Clinical has focused on state-of-the-art technology and systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of Avance Clinical’s trusted technology partners.
Visit http://www.avancecro.com for more information.
Recent Awards:
Excellence in Business Award 2021
Frost & Sullivan Asia-Pacific CRO Market Leadership Award 2020
Frost & Sullivan Asia-Pacific Customer Value Leadership Award 2021
Location: Australia, South Australia, Adelaide
Employees: 51-200
Founded date: 2019
Investors 1
Date | Name | Website |
28.03.2022 | The Rivers... | riversidec... |
Mentions in press and media 23
Date | Title | Description | Source |
21.09.2023 | AVANCE CLINICAL APPOINTS US-BASED EXECUTIVES - SVP SCIENTIFI... | ADELAIDE, Australia and RALEIGH, N.C., Sept. 21, 2023 /PRNewswire/ -- Avance Clinical, the award-win... | en.prnasia... |
23.11.2021 | At busy Visp site, Lonza will up microbial services by 5... | In an effort to up its development of microbial-derived proteins, Swiss CDMO Lonza will in... | endpts.com... |
23.11.2021 | Vaccibody gets a new name and loads up with nearly $1B in... | Vaccibody who? A little over a year after securing a $700 million-plus deal with Roche for it... | endpts.com... |
23.11.2021 | FDA approves pricey new treatment for ultra-rare and agg... | Forget the migraine marketing brand wars. When it comes to patients, many can’t even name one despit... | endpts.com... |
23.11.2021 | FDA approves pricey new treatment for ultra-rare and agg... | After a wild two-decade ride, the FDA has approved Takeda’s antiviral maribavir — now marketed as Li... | endpts.com... |
23.11.2021 | FDA approves pricey new treatment for ultra-rare and agg... | President Biden’s nominee to run the FDA was hit with some tepid criticism back in 2016 for being to... | endpts.com... |
23.11.2021 | A fledgling transpacific biotech grabs a launch round to ... | Precision-med biotech Allorion Therapeutics is expanding — and now has tens of millions o... | endpts.com... |
23.11.2021 | FDA approves pricey new treatment for ultra-rare and agg... | Horizon Therapeutics CEO Tim Walbert runs a rare disease company, but he’s also a patient. While his... | endpts.com... |
23.11.2021 | Covid-19 roundup: WHO looks to boost production of antib... | While Europe is in the midst of a massive fourth Covid-19 surge, the UK has largely avoided the high... | endpts.com... |
23.11.2021 | Dragonfly gets Merck on second TriNKET candidate sinc... | Dragonfly Therapeutics is doing better and better in getting Big Pharma on its TriNKET pl... | endpts.com... |
Show more